A case of no pain no gain for iX Biopharma

SINGAPORE (Oct 13): DBS Group Research has derived a fair value estimate of 43 cents for iX Biopharma in its preliminary assessment of what it deems a high-risk stock, with a view that investors should expect 0-20% potential returns from the stock over the next 12 months.

The specialty pharmaceutical company currently has five drugs under development: WafeRest for jetlag and improved sleep quality; PheoniX for the treatment of male erectile dysfunction; as well as Wafermine, BnoX and Wafernyl for pain management.

All five drugs leverage on an under-the-tongue delivery technology, WaferiX, which enables quicker absorption and increases the bioavailability of the drugs such that a lower dosage is required.

---

Related Stories

• iX Biopharma releases updates on two of its key strategic growth drivers
• iX Biopharma losses widen 12% y-o-y to $10.8 mil in FY2024
• Awak Technologies raises over US$20 mil in Series B funding

---